![Piet Wigerinck](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Piet Wigerinck
Direktor/Vorstandsmitglied bei
IPSEN
Vermögen: 124 266 $ am 31.05.2026
Profil
Derzeit ist Piet Wigerinck Chief Scientific Officer von Galapagos NV. Er ist auch im Vorstand von Ipsen SA und Ipsen Pharma SAS. In der Vergangenheit war er Vice President-Drug Discovery & Early Development bei Tibotec Pharmaceuticals und Vice President von Drug Discovery & Development Solutions Ltd. Dr. Wigerinck erhielt einen Doktortitel von der Katholieke Universiteit Leuven.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IPSEN SA 0% | 31.12.2025 | 680 ( 0% ) | 124 266 $ | 31.05.2026 |
Aktive Positionen von Piet Wigerinck
| Unternehmen | Position | Beginn |
|---|---|---|
| IPSEN | Direktor/Vorstandsmitglied | 01.05.2018 |
Antwerp University Hospital
 Antwerp University Hospital Hospital/Nursing ManagementHealth Services Provides clinical, patient care, academic training and scientific research services | Direktor/Vorstandsmitglied | - |
miDIAGNOSTICS NV
 miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services Develops a computer chip powered portable medical laboratory | Direktor/Vorstandsmitglied | - |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Develops anti-tumour medicine | Direktor/Vorstandsmitglied | - |
Symeres BV
 Symeres BV BiotechnologyHealth Technology Operates as a contract research organization for drug discovery and development activities | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Piet Wigerinck
| Unternehmen | Position | Ende |
|---|---|---|
| LAKEFRONT BIOTHERAPEUTICS NV | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2021 |
UZA Foundation | Direktor/Vorstandsmitglied | - |
Xinvento BV
 Xinvento BV BiotechnologyHealth Technology Operates as a biotech company that develops therapies for congenital hyperinsulinism | Gründer | - |
Tibotec Virco Comm. VA
 Tibotec Virco Comm. VA Pharmaceuticals: MajorHealth Technology Provides medicine | Corporate Officer/Principal | - |
| ░░░░ ░░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Piet Wigerinck
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
62
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Galapagos NV
 Galapagos NV BiotechnologyHealth Technology Manufactures and develops pharmaceutical products for oncology | Health Technology |
Antwerp University Hospital
Antwerp University Hospital Hospital/Nursing ManagementHealth Services Provides clinical, patient care, academic training and scientific research services | Health Services |
Tibotec Virco Comm. VA
Tibotec Virco Comm. VA Pharmaceuticals: MajorHealth Technology Provides medicine | Health Technology |
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services Develops a computer chip powered portable medical laboratory | Commercial Services |
Drug Discovery & Development Solutions Ltd.
 Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in drug discovery and development | Commercial Services |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Develops anti-tumour medicine | Health Technology |
Symeres BV
Symeres BV BiotechnologyHealth Technology Operates as a contract research organization for drug discovery and development activities | Health Technology |
Xinvento BV
Xinvento BV BiotechnologyHealth Technology Operates as a biotech company that develops therapies for congenital hyperinsulinism | Health Technology |
UZA Foundation |
